Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05804370 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT05804370 · ClinicalTrials.gov record · last posted 2026-07-14

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

Name: Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302) — clinical trial record (NCT05804370)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorNX Development Corp

Started2024-05-30

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This Phase 3 study is designed to investigate the safety, diagnostic performance, and clinical usefulness of Gleolan for the real-time detection and visualization of epithelial ovarian cancer tumors during debulking surgery. The study is planned to run for about 18 months with individual study participation lasting about two (2) weeks.

Amendment record 4 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 4 times since 2023-03-27; most recent amendment 2026-07-13. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-06-03

Status change Not Yet Recruiting→Recruitingv2

Trial Details

NCT Number	NCT05804370
Lead Sponsor	NX Development Corp
Conditions	Ovarian Cancer
Enrollment	170 participants
Start Date	2024-05-30
Primary Completion	2028-09 (estimated)
Study Completion	2029-05 (estimated)
Updated on ClinicalTrials.gov	2026-07-14